Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SION

Sionna Therapeutics Inc

Feb 10 • 04:00PM ET

22.24

Dollar change -2.76
Percentage change -11.04	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	42.52M	Perf Week	-
Market Cap	99.19M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	-	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-2.70	P/B	-	EPS next Y	-	ROA	-	Short Interest	-	Perf Year	-
Cash/sh	8.64	P/C	2.58	EPS next 5Y	-	ROE	-	52W Range	21.10 - 25.19	Perf YTD	-11.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-11.71%	Beta	-
Dividend TTM	-	Quick Ratio	4.88	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.40%	ATR (14)	3.62
Dividend Ex-Date	-	Current Ratio	4.88	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	- -
Employees	28	Debt/Eq	0.31	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.29	EPS Q/Q	-	Payout	-	Rel Volume	0.08	Prev Close	25.00
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.89M	Price	22.24
SMA20	-5.84%	SMA50	-5.84%	SMA200	-5.84%	Trades		Volume	143,952	Change	-11.04%

Today 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development - to fully normalize the function of CFTR, the key protein leading to the pathology of CF - has remained out of reach.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Peter A.	Director	Feb 10 '25	Buy	18.00	550,000	9,900,000	3,704,959	Feb 10 04:05 PM
Booth Bruce	Director	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM
Atlas Venture Fund XI, L.P.	10% Owner	Feb 10 '25	Buy	18.00	60,000	1,080,000	807,727	Feb 10 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your FINVIZ experience